NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
New data reinforces findings from MINDACT supporting MammaPrintยฎ in predicting chemotherapy benefit for distant recurrence free interval among patients with HR+HER2-early-stage breast cancerย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 11, 2024 โ Read More
Agendia Announces Publication Validating MammaPrint Utility in Prediction of Extended Endocrine Therapy Benefit
A secondary analysis of the randomized controlled trial, IDEAL, confirms results from NSABP B-42 demonstrating MammaPrint is predictive of extended endocrine therapy benefit IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 2, 2024 โ Read More
Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024
New data reinforces MammaPrintยฎ and BluePrintยฎ testsโ expanding clinical utility to optimize treatment selection. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ November 25, 2024 โ Agendiaยฎ, Inc., announced today that new data on its Read More
Newsroom
News, Stories & Breast Cancer Blog
Hormonal Therapy Story: How Laura-Lynn Renner Made an Informed Choice
By Kris Conner | August 7, 2024 How the diagnostic test MammaPrint empowered Laura-Lynn to find answers and advocate to improve the quality of her life. In the summer of 2020, Laura-Lynn Renner, a Read More
What Is Chemotherapy?
Along with surgery or radiation therapy, chemotherapy is one of the most common ways to treat cancer. Chemotherapy treatment is designed to destroy cancer cells; it can be used for primary cancer (cancer that Read More
Anthracycline Plus Chemo Associated With Improved RFS in MP High-2โRisk, HR+/HER2โ Early Breast Cancer
By Ryan Scottย June 1, 2024 Key Takeaways Patients with MammaPrint high-2, BluePrint Luminal B, HR-positive, HER2-negative early breast cancer had better 3-year RFS with anthracycline plus a taxane and cyclophosphamide. Luminal MP high-1โrisk Read More
Improved RFS Seen with Anthracycline Plus Chemo in MP High-2โRisk, HR+/HER2โ Early Breast Cancer
By Ryan Scottย June 1, 2024 A lower risk of disease recurrence was seen when combining anthracycline and chemotherapy to treat certain patients with breast cancer. Anthracycline plus a taxane and cyclophosphamide was linked to Read More
Coffee with America: Dr. William Audeh for Agendia Breast Cancer Subtyping
Discover why understanding the specific characteristics of breast cancer is crucial for developing personalized treatment strategies that can significantly improve outcomes. Dr. William Audeh, a leading medical oncologist specializing in breast cancer and Agendia Read More
Genomic Testing Transforms Breast Cancer Care and Treatment Success
In an insightful interview with Dr. William Audeh, MD, MS, Chief Medical Officer at Agendia, featured in ONCOLife, we explore the pioneering strides in genomic testing within breast cancer treatment. Dr. Audeh, shares his Read More
Recognizing Common Breast Cancer Symptoms & the Importance of Early Detection
Breast cancer is the most common cancer among women, with about 1 in 8 women being diagnosed in their lifetime.[1] It also accounts for nearly 30% of all new female cancer diagnoses each year, with Read More